Resolution Therapeutics
Generated by Meeveem AI
"Pioneering regenerative macrophage therapies to transform outcomes in inflammatory organ diseases"
Edinburgh
•51 - 250 Employees
•Biotechnology
About Resolution Therapeutics
Resolution Therapeutics develops regenerative macrophage therapies to treat inflammatory and fibrotic diseases. The company focuses on patients with advanced liver cirrhosis, creating cell therapies designed to repair damaged organs and prevent transplantation. By engineering macrophages, the cells the body uses to resolve injury, Resolution delivers treatments that digest scar tissue, halt inflammation and promote regeneration. Built on over a decade of University of Edinburgh research, the company brings together macrophage biology, cell engineering and manufacturing. Resolution's lead therapy is in Phase 2 trials, demonstrating how regenerative macrophages reduce complications in end-stage liver disease.
74
Team Members
2017
Founded
Biotechnology
Sector
On-Site
Work Environment
Our Vision
A world where inflammatory and fibrotic organ diseases are reversible through the body's own regenerative capacity enhanced by engineered cell therapy
Our Mission
Developing the first autologous anti-inflammatory and anti-fibrotic macrophage cell therapy for inflammatory organ diseases to prevent complications and transplants in patients with end-stage liver disease